JPRN-jRCT2021200043进行中（未招募）3 期
Japanese phase III study of IDEC-C2B8-SC for previously untreated B cell Follicular lymphoma. - IDEC-C2B8-SC1
Okugaito Izumi0 个研究点目标入组 44 人开始时间: 2021年3月31日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •1. Japanese patients with follicular lymphoma grade 1, 2, or 3a , according to the WHO classification system (2017)
- •2. No prior follwing treatment for non-Hodgkin lymphoma : chemotherapy, antibody therapy, immunosuppressive chemotherapy, radioimmunotherapy, hematopoietic stem-cell transplantation
- •3. Patients with at least one of GELF criteria
- •4. ECOG performance status of 0-2
- •5. Age 20 years or more, but age 80 years or younger at the time of informed consent
- •6. Life expectancy of 6 months or more
- •7. Written informed consent
排除标准
- •1. Histologically proven transformation after the diagnosis of follicular lymphoma grade 1, 2 or 3a
- •2. Patients with HIV antibody. Patients with active hepatitis infection. One or more positive test results for HBs antigen, HBs antibody, HBc antibody or HCV antibody.
- •3. Patients with diabete treating with insulin
- •4. Patients with active multiple cancer
- •5. Patients with severe heart disease or lung disease
- •6. CNS involvement of lymphoma
- •7. Patients with severe psychological conditions
- •8. Pregnancy or nursing females
研究者
相似试验
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast CancerStage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast CancerMedDRA version: 18.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005156-94-ESilly S.A.75
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast CancerStage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast CancerMedDRA version: 19.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005156-94-FREli Lilly and Company75
进行中（未招募）
2 期
Phase 2 study of BK1901 as a Booster in Japanese childrePrevention of pertussis, diphtheria, tetanus, and acute poliomyelitisJPRN-jRCT2031200412Fuji Hideyuki200
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast CancerStage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005156-94-BEEli Lilly and Company75
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast CancerStage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005156-94-ITEli Lilly and Company75